Table I.
Baseline characteristics of patients with HCC.
| Variable | Patients |
|---|---|
| Age, median years (range) | 56 (31–81) |
| Gender, n | |
| Male | 44 |
| Female | 6 |
| Child-Pugh score, n | |
| A | 44 |
| B | 6 |
| BCLC stage, n | |
| B | 26 |
| C | 24 |
| ECOG PS, n | |
| 0 | 23 |
| 1 | 27 |
| Number of lesions, n | |
| 1 | 22 |
| ≥2 | 28 |
| Hepatitis virus, n | |
| HbsAg positive | 42 |
| Anti-HCV positive | 2 |
| HbsAg and anti-HCV, n | |
| Positive | 2 |
| No | 4 |
| AFP, n | |
| <400 ng/ml | 24 |
| ≥400 ng/ml | 26 |
| AST/ALT, n | |
| <2 | 8 |
| ≥2 | 42 |
| Vascular invasion, n | |
| Yes | 23 |
| No | 27 |
| Extrahepatic metastasis | |
| Pathological confirmation, n | |
| Yes | 7 |
| No | 43 |
| Yes | 7 |
| No | 43 |
| Previous therapy | |
| TACE, n (median cycle; cycle range) | 43 (3; 1–12) |
| TACE combined with sorafenib, n | 7 |
| Surgical resection, n | 6 |
| Radiofrequency therapy, n | 4 |
| Radiotherapy, n | 2 |
HCC, hepatocellular carcinoma; BCLC, Barcelona Clinic Liver Cancer; ECOG PS, Eastern Cooperative Oncology Group performance status; AFP, α-fetoprotein; AST/ALT, aspartate aminotransferase/alanine aminotransferase (AST/ALT); TACE, transcatheter arterial chemoembolization.